达格列净联合缬沙坦胶囊在2型糖尿病合并新发高血压患者中的应用效果

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of Daglijing combined with Valsartan Capsules in patients with type 2 diabetes mellitus complicated with newly developed hypertension.Methods A total of 92 patients with type 2 diabetes mellitus complicated with newly developed hypertension who were admitted to the Department of Endocrinology in Beijing Jiangong Hospital from January to December 2019 were selected as the research objects.All the patients were divided into combination therapy group and monotherapy group by the random number table method,with 46 cases in each group.Patients in the combination therapy group were treated with Daglijing combined with Valsartan Capsules,and patients in the monotherapy group were treated with Valsartan Capsules.After 24 weeks of treatment,the systolic blood pressure(SBP),diastolic blood pressure(DBP),mean artery pressure(MAP),SBP control rate,DBP control rate,and both control rate of the two groups were compared.Results A total of 41 patients in the combined treatment group and 40 patients in the monotherapy group were included in statistical analysis.There were no statistically significant differences in SBP,DBP,MAP before treatment between the two groups(P＞0.05).The SBP,DBP and MAP of the two groups after treatment were lower than those before treatment,and the differences were statistically significant(P＜0.05).The SBP,DBP and MAP of the combination therapy group after treatment were lower than those in the monotherapy group,and the differences were statistically significant(P＜0.05).After treatment,the SBP compliance rate and both compliance rates in the combined treatment group were higher than those in the monotherapy group,and the differences were statistically significant(P＜0.05).There was no statistical significance in DBP compliance rate between the two groups(P>0.05).Conclusion The clinical effect of Daglijing combined with Valsartan Capsules is better in patients with type 2 diabetes mellitus complicated with newly developed hypertension.

Key words： Daglijing Valsartan Capsules Diabetes mellitus Hypertension

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HAO Yan-hong
	WU Qing
	LI Yun
	WANG Ying-li
	ZHANG Ying
	LUO Ya-hui
	LIU Yan-dong
	ZHOU Li-jing

Cite this article:

HAO Yan-hong,WU Qing,LI Yun, et al. Application effect of Daglijing combined with Valsartan Capsules in patients with type 2 diabetes mellitus complicated with newly developed hypertension[J]. 中国当代医药, 2021, 28(17): 67-70.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I17/67

[1]	张正姬，武鸣，张宁，等.苏州市2 型糖尿病患者血糖、血压、血脂达标情况分析[J].中国公共卫生管理，2019，35（3）：301-304.
[2]	夏小娟，陈春霞，张海洋，等.南京市江宁区2 型糖尿病合并高血压患者血压控制及影响因素[J].江苏预防医学，2019，30（3）：272-275.
[3]	陈璐，陈伟珍，王莎莎，等.高尿酸血症对维持性血液透析患者心血管危险因素聚集及相关并发症的影响[J].中国现代医生，2020，58（3）：105-108，112.
[4]	张建平.糖尿病、高血压人群心脑血管事件的发生情况及影响因素[J].临床合理用药杂志，2020，13（23）：147-148.
[5]	Paul M，Paul KW，Mark W，et al.A Comparison of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline and the 2017 American Diabetes Association Diabetes and Hypertension Position Statement for U.S.Adults With Diabetes[J].Diabetes Care，2018，41（11）：2322-2329.
[6]	Gao N，Yuan Z，Tang X，et al.Prevalence of CHD-related metabolic comorbidity of diabetes mellitus in Northern Chinese adults：the REACTION study[J].Diabetes Complications，2016，30（2）：199-205.
[7]	韩胜红，张佩君，李俊琳，等.湖北省35～75 岁居民高血压、糖尿病、高血脂患病及共病影响因素分析[J].应用预防医学，2019，25（5）：356-360.
[8]	马志刚，左庆瑶.中老年糖尿病合并高血压患者心脑血管事件发生情况分析[J].中国医药，2017，12（9）：1306-1309.
[9]	马一涵，李兴雨，刘倩，等.高血压患者血压达标次数对心脑血管疾病发病的影响研究[J].中国全科医学，2020，23（28）：3608-3614.
[10]	方凯，马爱娟，董晶，等.北京市糖尿病合并高血压患者心血管疾病危险因素控制现状[J].中国慢性病预防与控制，2019，27（11）：830-833.
[11]	牟伦盼，蒋建家，张雅萍，等.达格列净与利格列汀对口服降糖药控制不佳的超重或肥胖2 型糖尿病患者的疗效和安全性比较[J].中华糖尿病杂志，2019，11（3）：190-195.
[12]	刘诗苑，李晓雯，黄明炜，等.达格列净联合胰岛素强化治疗难治性2 型糖尿病的疗效观察[J].中国临床研究，2020，33（9）：1207-1210.
[13]	赵香芳，常连庆，吕春雷，等.达格列净治疗2型糖尿病的研究进展[J].医学综述，2021，27（4）：783-787.
[14]	邓宁，胡庆芬，梁彩虹，等.达格列净片联合盐酸二甲双胍对2 型糖尿病患者的临床研究[J].中国临床药理学杂志，2019，35（18）：2016-2018.
[15]	中华医学会糖尿病学分会.中国2 型糖尿病防治指南（2017年版）[J].中国实用内科杂志，2018，38（4）：292-344.
[16]	中国高血压防治指南修订委员会，高血压联盟，中华医学会心血管病学分会中国医师协会高血压专业委员会，等.中国高血压防治指南（2018年修订版）[J].中国心血管杂志，2019，24（1）：24-56.
[18]	顾亦斌，薛雨星，盛红艳，等.2013年常熟市2 型糖尿病患者的血糖、血脂及血压控制情况及影响因素分析[J].实用预防医学，2019，26（7）：836-840.
[19]	李晓明.缬沙坦联合硝苯地平控释片治疗原发性高血压的效果分析[J].中国实用医药，2020，15（5）：115-117.
[20]	黄小区，潘洁婷，邝恒幸，等.达格列净联合二甲双胍对老年T2DM 患者血糖水平及心血管危险因素的影响[J].广州医科大学学报，2020，48（4）：24-28.
[17]	Reboldi G，Gentile G，Angeli F，et al.Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes：a meta-analysis in 73 913 patients[J].J Hypertens，2011，29（7）：1253-1269.
[21]	范晓霞，姚勇利，胡耀嘉，等.超重和肥胖2 型糖尿病伴微量白蛋白尿患者使用达格列净或沙格列汀控制血糖疗效和安全性的观察[J].中国糖尿病杂志，2020，28（2）：85-88.
[22]	陈展祥.苯磺酸氨氯地平联合缬沙坦治疗高血压的临床疗效分析[J].中国现代药物应用，2020，14（18）：147-149.